RNAi

Alnylam scraps trial in rare eye disorder, blaming drug price reforms
Pharmaphorum
Fri, 10/28/22 - 10:25 am
Alnylam
RNAi
vutrisiran
Stargardt disease
Inflation Reduction Act
drug pricing
Biotech’s near-term key catalysts
EP Vantage
Thu, 09/29/22 - 09:45 am
Biogen
Eisai
Alzheimer's disease
Arrowhead Pharmaceuticals
Takeda
RNAi
Madrigal
NASH
Ascendis
FDA
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Businesswire
Mon, 08/29/22 - 10:26 am
Alnylam Pharmaceuticals
clinical trials
cemdisiran
Regeneron
IgAN
immunoglobultin A nephropathy
RNAi
Alnylam's potential fourth RNAi approval delayed three months, but impact likely to be 'modest'
Endpoints
Mon, 04/4/22 - 11:08 pm
Alnylam
RNAi
FDA
vutrisiran
Another biotech shuffles its C-suite as Silence CEO steps down
Endpoints
Tue, 02/22/22 - 10:54 am
Silence Therapeutics
Pharma CEOs
RNAi
GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowhead
Fierce Biotech
Mon, 11/22/21 - 10:19 pm
GSK
Arrowhead Pharmaceuticals
NASH
RNAi
Novo Nordisk bets big on RNAi, paying $3.3B to buy Dicerna
Fierce Biotech
Thu, 11/18/21 - 10:54 am
Novo Nordisk
M&A
Dicerna Pharmaceuticals
RNAi
Dicerna's RNAi drug shows 'inconsistent' results in rare kidney disease, tanking shares despite trial win
Endpoints
Thu, 08/5/21 - 11:24 pm
Dicerna
RNAi
Primary Hyperoxaluria
clinical trials
Alnylam's Study on Renal Treatment Shows Promising Results In Phase III Trial
BioSpace
Mon, 08/2/21 - 11:06 am
Alnylam
RNAi
renal decline
clinical trials
lumasiran
Arrowhead rocked by animal tox issues again, hitting the pause button on RNAi study in cystic fibrosis
Endpoints
Fri, 07/2/21 - 11:04 am
Arrowhead Pharmaceuticals
RNAi
animal research
cystic fibrosis
Eli Lilly Collab Scores IND Approval for Dicerna's RNAi Cardiometabolic Drug
BioSpace
Thu, 05/27/21 - 11:09 am
Dicerna
Eli Lilly
LY3819469
clinical trials
RNAi
cardiometabolic diseases
Novartis’s big wager on RNAi approaches the finish line
EP Vantage
Wed, 11/25/20 - 10:27 am
Novartis
RNAi
COVID-19
Leqvio
cholesterol
Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?
Motley Fool
Sun, 10/18/20 - 08:32 pm
Alnylam
Vir Biotechnology
RNAi
vaccines
COVID-19
Takeda drops $300M cash to kick off $1B RNAi alliance with Arrowhead, shooting for first-in-class rare disease drug
Endpoints
Thu, 10/8/20 - 10:59 am
Takeda
RNAi
Arrowhead Pharmaceuticals
Rare Diseases
Alnylam phase 3 links lumasiran to 'clinically significant' improvement in infants
Fierce Biotech
Wed, 09/30/20 - 10:35 am
Alnylam
clinical trials
lumasiran
RNAi
PH1
Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug
Xconomy
Wed, 09/16/20 - 07:28 pm
Arrowhead Pharmaceuticals
clinical trials
liver disease
RNAi
ARO-AAT
New data from J&J, Arrowhead mark latest step in RNAi's hepatitis B race
BioPharma Dive
Sat, 08/29/20 - 11:42 pm
Arrowhead Pharmaceuticals
JNJ
clinical trials
RNAi
hepatitis B
J&J's RNAi suppresses hepatitis B for 48 weeks after last dose
Fierce Biotech
Fri, 08/28/20 - 10:47 am
JNJ
RNAi
JNJ-3989
hepatitis B
EASL 2020 – Assembly finds a partner as hepatitis B inches forward
EP Vantage
Fri, 08/28/20 - 10:34 am
EASL
RNAi
hepatitis B
Assembly Biosciences
Abrutus
JNJ
GSK
Vir Biotechnology
Regeneron flashes ‘great advance' in the NEJM for that other cholesterol drug sitting at the FDA
Endpoints
Wed, 08/19/20 - 11:45 pm
Regeneron
inclisiran
RNAi
Novartis
New England Journal of Medicine

Pages